Lun - Ven 8:00 - 17:00
^ a b c The United States Food and Drug Administration, FDA (June 2017).
"Efficacy and Safety of On-Demand Use cenforce 150 uk of 2 Treatments Designed for Different Etiologies of Female Sexual Interest/Arousal Disorder: 3 Randomized Clinical Trials". "Genotype scores predict drug efficacy in subtypes of female sexual interest/arousal disorder: A double-blind, randomized, placebo-controlled cross-over trial". "Toward Personalized Sexual Medicine (Part 3): Testosterone Combined with a Serotonin1A Receptor Agonist Increases Sexual Satisfaction in Women with HSDD and FSAD, and Dysfunctional Activation of Sexual Inhibitory Mechanisms". "Sex Offenders Seeking Treatment for Sexual Dysfunction—Ethics, Medicine, and the Law". "Flibanserin: A Novel, Nonhormonal Agent for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women".
"Onsite pharmacist program in medical homes declared a success". International Journal of Psychiatry in Clinical Practice. "US Food and Drug Administration Approval of Addyi (Flibanserin) for Treatment of Hypoactive Sexual Desire Disorder". "Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis". "FDA Approval of Flibanserin — Treating Hypoactive Sexual Desire Disorder".
^ a b English, Clayton; Muhleisen, Anne; Rey, Jose A. "Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women". P & T: A Peer-Reviewed Journal for Formulary Management. ^ The United States Food and buy super p force jelly Drug Administration, FDA (December 2025). "New Drug for Hypoactive Sexual Desire Disorder in Premenopausal Women". "TRIPTODUR (triptorelin) for extended-release injectable suspension, for intramuscular use" (PDF).
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Gold | 100 mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Kamagra | 100mg | 20 Pills | 86.09€ 81.99€ | |
| Cialis Generic | 5mg | 360 + 10 Pills | 268.08€ 255.31€ | |
| Cialis Generic | 60mg | 270 + 10 Pills | 443.96€ 422.82€ | |
| Kamagra Oral Jelly | 100 mg | 90 + 8 Sachets | 303.56€ 289.10€ | |
| Cialis Soft Tabs | 20mg | 60 + 4 Pills | 159.37€ 151.78€ | |
| Cialis Generic | 60mg | 360 + 10 Pills | 570.52€ 543.35€ | |
| Levitra Generic | 20mg | 90 + 8 Pills | 180.78€ 172.17€ | |
| Cialis Original | 20mg | 64 + 4 Pills | 274.18€ 261.12€ | |
| Cialis Professional | 40mg | 120 + 4 Pills | 436.68€ 415.89€ | |
| Viagra Generic | 25mg | 30 + 4 Pills | 47.97€ 45.69€ | |
| Priligy Generic Dapoxetine | 60mg | 60 + 8 Pills | 183.06€ 174.34€ | |
| Levitra Professional | 20mg | 20 Pills | 101.00€ 96.19€ | |
| Viagra Professional | 100mg | 90 + 2 Pills | 207.09€ 197.23€ | |
| Levitra Generic | 10mg | 90 + 8 Pills | 150.58€ 143.41€ |
Archived from the original (PDF) on October 19, 2020.
Yen and Jaffe's Reproductive Endocrinology (Eighth ed.). {{cite book}}: CS1 maint: multiple names: authors list (link) ^ a b c The United States Food and Drug Administration, FDA (March 2012). Archived from the original (PDF) on January 18, 2017. ^ a b c The United States Food and Drug Administration, FDA (2008-09-13). Archived from the original (PDF) on March 2, 2013. ^ a b c Surgical Management of the Transgender Patient.
"Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs". "Practical differences between luteinizing hormone-releasing hormone agonists in prostate cancer: perspectives across the spectrum of care". ^ a b c d The United States Food and Drug Administration, FDA (January 2012). Archived from the original (PDF) on November 6, 2015. ^ a b c d "Gonadotropin Releasing Hormone (GnRH) Analogues", LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2018-03-20, PMID 31643199, retrieved 2021-03-28 "A Clinical Approach to Catamenial Epilepsy: A Review". ^ a b c d e "Androcur 50 mg Tablets - Summary of Product Characteristics (SmPC) - (emc)".
(2018-06-19), Feingold, Kenneth R.; Anawalt, Bradley; Boyce, Alison; Chrousos, George (eds.
[38][41] In addition to this mechanism, it also competes for the androgen receptors against testosterone and dihydrotestosterone, causing interference with the androgen-receptor interaction on the reproductive organ, thereby lowering sexual desire. Cyproterone acetate has been proven effective in restraining sexual drive and fantasies in patients with high libido. [5] Its usage in treating hypersexuality has been advocated by the World Federation of Societies of Biological Psychiatry (WFSBP). Common tadalista professional adverse effects of cyproterone acetate include depression, hepatotoxicity, dyspnea, change in body weight, hot flushes, sweating, fatigue, and gynaecomastia. Cyproterone acetate is mainly orally administered to the body, and it has a half-life of 1.8 days.
[29][39][42] After metabolism, its metabolites are predominantly excreted via faeces. There are many types of drugs that unintentionally lower sexual desire through indirect mechanisms. It is one of their side-effects as the outcome of libido suppression is not intended. SSRIs reduce the re-uptake of serotonin back to the neurons, leading to an increase in serotonin level in the body. Due to the fact that serotonin can interfere with other neurotransmitters and hormones, for instance, sex hormones, SSRIs can therefore lower sexual desire.
Apart from SSRIs, other types of drugs that could lower sexual desire are not intended to suppress libido originally. Thus, sexually active people are suggested to avoid the usage of the following drugs:[44] Non-steroidal anti-inflammatory drugs (e.g. Postmenopausal women may also suffer from HSDD due to a decline in androgen production from menopause. [6] A research proposed two combinations of drugs, each designed against the different causes of HSDD. One combination is to utilise sublingual testosterone with a 5-HT1A receptor agonist to raise motivation for sex, by lifting the inhibition mechanisms in the brain's prefrontal regions. "Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer—A Comprehensive Review".
^ Simon, James A.; Kingsberg, Sheryl A.; Portman, David; Williams, Laura A.; Krop, Julie; Jordan, Robert; Lucas, Johna; Clayton, Anita H. (November 2019). "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder". ^ The United States Food and Drug Administration, FDA (June 2019). Archived from the original (PDF) on June 22, 2019. "Transgender adults, gender-affirming hormone therapy and blood pressure: a systematic review".
| Cause Category | Specific Causes | Symptoms | Typical Treatments | Notes |
|---|---|---|---|---|
| Physical Factors | Cardiovascular disease | Erectile failure | Medications, lifestyle changes | Underlying health condition treated |
| Psychological Factors | Anxiety, depression | Reduced libido, ED | Counseling, therapy | Often co-occurs with physical causes |
| Hormonal Imbalance | Low testosterone | Fatigue, decreased libido | Hormone replacement therapy | Medical evaluation needed |
^ "What types of drugs have general sexual side effects?".
| Test Name | Purpose | Procedure Description | Advantages | Limitations |
|---|---|---|---|---|
| Nocturnal Penile Tumescence Test | Distinguish physical vs psychological causes | Measures spontaneous erections during sleep | Non-invasive, simple | Not definitive alone |
| Duplex Ultrasound | Assess blood flow to penis | Ultrasound with Doppler | Detects vascular issues | Requires specialist equipment |
| Blood Tests | Check hormone levels, health status | Blood sample analysis | Identifies underlying health issues | May be fasting required |
Access patient specific medications for your clinic and patients or medications in large-scale for healthcare systems.
[5] Patients who were prescribed with these drugs have sexual thoughts less frequently and strongly. Common adverse effects elicited by these drugs include hot flushes, bone loss, headache, unpredictable mood changes, depression, vaginal dryness, or even atrophy for females and penile atrophy for males. [34] These adverse effects can be counteracted and treated by add-back therapy, also known as hormone replacement therapy. People treated with GnRH agonists are suggested to undergo this therapy simultaneously by taking adequate progestin, vitamin D, and calcium supplement pills daily. Gonadotropin-releasing hormone agonists are largely parenterally administered to the body, that is, via subcutaneous or intramuscular injection.
[30][32][35][36][37] At the same time, nafarelin is an exception in which its prescription is a nasal spray, and some may be implanted into fats. [31] In general, their half-lives are approximately two to four hours. [31][35][36][37] Some agonists are mainly excreted via urine while other agonists are mainly excreted via faeces. Steroidal anti-androgens are a class of steroid drugs that inhibit the actions of androgens. Cyproterone acetate, a 17-hydroxyprogesterone acetate derivative, is a very potent one and is widely used.
[29] Though it is not approved by the US FDA owing to its toxicity, it has been approved by Canada and a plethora of countries in Europe with the brand name Androcur in the market. [29][38][39] This drug mainly targets men due to its mechanism of action. Cyproterone acetate suppresses libido by directly reducing the level of active androgen, testosterone, in males. The suppression of testosterone level results from its inhibition of the release of luteinizing hormone (LH) from the anterior section of the pituitary gland, interfering with testosterone production from the testes as LH stimulates testosterone production. [32][39][40] It also blocks the conversion of testosterone to dihydrotestosterone for action. Nationwide Shipping & Compliance Assurance – Serving clinics, hospitals, and wellness centers.
[6][7][8] Testosterone is also proposed to be coupled with the PDE5 inhibitor, targeting an insensitive system for the production of sexual desire. [6][7][8] As both clinical trials showed desirable results, this indicates the prosperity of further developing a single drug targeting HSDD for all women of different status, even though the FDA has not approved the two combinations. In fact, HSDD was defined shortly before the release of flibanserin to the market and its approval by the US FDA. This has brought up a controversy about whether it is appropriate and ethical to create a medical condition for the benefit of the sales of pharmaceutical products. Apart from this ethical issue, there is a dilemma of whether a medical doctor should prescribe drugs to sexual offenders whose libido is subpar.
On the one hand, it is considered unethical for doctors not to treat them as they are expected to treat patients indiscriminately. On the other hand, treating sexual offenders may impose a risk to society. Physicians have been struggling with this dilemma, and it is still difficult for them to make a choice at this moment in time. "Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder". "Brain Mechanisms of Sexual Desire, Pleasure, And Inhibition".
"Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder". ^ a b c DeRogatis, Leonard; Rosen, Raymond C.; Goldstein, Irwin; Werneburg, Brian; Kempthorne-Rawson, Joan; Sand, Michael (March 2012). "Characterization of Hypoactive Sexual Desire Disorder (HSDD) in Men". "Treatment of Paraphilic Disorders in Sexual Offenders or Men With a Risk of Sexual Offending With Luteinizing Hormone-Releasing Hormone Agonists: An Updated Systematic Review". "Toward Personalized Sexual Medicine (Part 1): Integrating the "Dual Control Model" into Differential Drug Treatments for Hypoactive Sexual Desire Disorder and Female Sexual Arousal Disorder". We follow the highest safety and quality standards in IV compounding.
Our 503A and 503B IV medications are tested for sterility, potency,
and endotoxins, ensuring compliance with cGMP, USP <797>, and FDA regulations.
Années d'expérience
Domaines d'interventions
Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse
En savoir plus
L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.
En savoir plus
L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.
En savoir plus
Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.
En savoir plusNos Projets
ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.
Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.
Question à nous poser
Nos Statistiques
Années d'expérience
de superficies reboisées
personnes sensibilisées
personnes autonomisées
Stagiaires et bénévoles formés pour suivi de la biodiversité
Nos Actualités